Physician profile

Robert R Orr

Pulmonary Disease · Peoria, AZ

NPI 1003809930

$11,748.73

in general payments reported to CMS, 2019-2025

59 companies · $4,310 in 2025

The $4,310 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,439.25
Education$454.72

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,500.91 2019-2025 Fasenra, Airsupra, Tezspire
Glaxosmithkline, LLC. $1,472.76 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Genzyme Corporation $1,216.10 2020-2025
Regeneron Healthcare Solutions, INC. $954.47 2019-2025 Dupixent
Boehringer Ingelheim Pharmaceuticals, INC. $598.16 2019-2025 Ofev, Stiolto Respimat, Jascayd
Electromed, INC. $481.93 2022-2025 Smartvest
Insmed, INC. $432.86 2020-2025 Arikayce, Brinsupri
Harmony Biosciences LLC $423.29 2021-2025 Wakix
Medical Graphics Corporation $410.35 2019
Jazz Pharmaceuticals INC. $330.28 2023-2025
Baxter Healthcare $301.59 2024-2025 Hillrom - Vest System Model 105 Home Care
Mylan Specialty L.P. $301.33 2019-2024 Yupelri
Grifols USA, LLC $292.92 2019-2025 Prolastin-C Liquid
Genentech USA, INC. $290.80 2019-2025 Xolair
Sanofi-Aventis U.S. LLC $253.73 2023-2025
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Verona Pharma, INC. $243.55 2025 Ohtuvayre
Novartis Pharmaceuticals Corporation $232.60 2019-2025
Philips North America LLC $212.60 2019-2025 Vest Therapy Und, (8874) Incourage
Actelion Pharmaceuticals US, INC. $203.63 2019-2025 Opsumit, Uptravi
Inspire Medical Systems, INC. $140.54 2023-2025 Inspire
United Therapeutics Corporation $123.95 2019-2025 Tyvaso, Tyvaso
Takeda Pharmaceuticals U.S.A., INC. $123.16 2024-2025 Glassia
Avadel Cns Pharmaceuticals, LLC $115.97 2024-2025 Lumryz
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $101.08 2021-2023 Trulance, Xifaxan
Ani Pharmaceuticals, INC. $98.66 2025 Purified Cortrophin Gel
Sunovion Pharmaceuticals INC. $74.66 2019-2020
Amgen INC. $73.11 2025 Tezspire
Pfizer INC. $72.58 2020-2023
Inogen, INC. $72.34 2023-2025 Inogen One G5 Oxygen Concentrator - Bluetooth
Vifor Pharma, INC. $66.41 2024 Zemaira
Pulmonx Corporation $53.02 2024-2025 Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter
Novo Nordisk INC $51.33 2022
Viatris Specialty LLC $50.57 2025 Yupelri
Vapotherm INC $44.11 2021
Lilly USA, LLC $43.26 2025 Zepbound, Mounjaro
Phadia US INC. $40.26 2023-2024 Immunocap
Abbott Laboratories $35.45 2023 Assurity, Eterna
Lucid Diagnostics INC. $29.86 2022
Advanced Respiratory, INC $28.83 2021
Merck Sharp & Dohme LLC $25.30 2024 Recarbrio, Zerbaxa
Boston Scientific Corporation $25.09 2024
Nestle Healthcare Nutrition INC. $24.98 2021
Eisai INC. $19.94 2020
Bayer Healthcare Pharmaceuticals INC. $18.00 2019
Optos, INC. $15.71 2021
Shire North American Group INC $13.75 2019
Tactile Systems Technology INC $12.95 2023 Entre Plus, Flexitouch Plus

12 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert R Orr

$11,748.73

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $4,310 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/90728/robert-r-orr

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.